Celgene is making a billion dollar bet on game-changing science.

On Tuesday, the biotech ponied up $1 billion to gain access to innovative cancer treatments being developed by Juno Therapeutics. The deal gives Celgene a 10% stake in Juno, as well the rights to sell the company’s therapies around the world. It’s the largest up-front sum for a biotechnology licensing agreement ever, according to Bloomberg Intelligence.

Juno  JUNO 2.10%  has been working on a series of CAR-T drugs, which stands for chimeric antigen receptor therapy. These treatments supercharge the body’s immune response to more directly and effectively target cancers. Celgene’s  CELG 2.15%  investment is a huge sign of confidence in the emerging therapy.

CAR-Ts improve on existing immunotherapies by removing disease-fighting T cells from the blood and re-engineering them to target cancer cells with near laser-like focus. This overcomes two clinical problems when it comes to fighting cancer, said Stephen Ansell, a doctor at the Mayo Clinic specializing in cancer and blood disorders.

For more details, go to: http://fortune.com/2015/06/30/celgene-juno-therapeutics-cancer/